Bullous pemphigoid
MONDO:0019082Bullous pemphigoid (BP) is the most common form of autoimmune bullous dermatosis.
Also known as: bullous pemphigoid, Old Age pemphigus, Parapemphigus, benign pemphigus, senile dermatitis herpetiformis
52 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study tests an injection called stapokibart for people with moderate to severe bullous pemphigoid, a painful blistering skin condition. The goal is to see if it can help patients stop taking steroids and keep the disease under control for 36 weeks. About 200 adults aged 18 t…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC